503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
2026 Head-to-Head Fee & Dose-Escalation Teardown · DOI 10.5281/zenodo.24139315

PlushCare vs. Losing Weight RX (2026 Cost Audit): $19.99/mo Membership + $129 Visit Fees + Retail Rx

Audited 52-Week Cost Verdict

In our 2026 52-week pharmacoeconomic audit (DOI 10.5281/zenodo.24139315), PlushCare totals $13,259 over 13 four-week cycles ($105.21/mg at 2.4 mg semaglutide maintenance) due to bills per-visit physician consult fees plus monthly membership without bundling affordable flat-rate 503a medication. Losing Weight RX locks Semaglutide at $49/mo ($588/52 weeks, $5.10/mg) and Tirzepatide at $99/mo ($1,188/52 weeks) with $0 membership fees.

Audit DimensionPlushCareLosing Weight RX (Verified Lock)
Billing Structure$19.99/mo Membership + $129 Visit Fees + Retail Rx$49/mo Semaglutide · $99/mo Tirzepatide All-Inclusive
Mandatory Monthly MembershipIncluded in $13,259 total above$0.00 / month
High-Dose Escalation Surcharge (2.4mg / 15mg)Applies on tiered/retail plans$0.00 (Same Flat Price All Doses)
Effective $/mg (2.4 mg/wk Semaglutide)$105.21/mg$5.10 / mg
Minimum Contract Commitment1 Month1 Month (Cancel Anytime)
52-Week Cumulative Semaglutide Spend$13,259$637 (13 Four-Week Cycles @ $49)

Key Consumer Finding: PlushCare

Bills per-visit physician consult fees plus monthly membership without bundling affordable flat-rate 503A medication.

Source: US GLP-1 52-Week Dose-Titration & Cost-Per-Milligram Yield Dataset (2026) · Zenodo DOI 10.5281/zenodo.24139315.

Switch Without Restarting at Starter Doses

Keep your current prescribed titration tier at $49/mo Semaglutide or $99/mo Tirzepatide—with $0 monthly platform dues.

Switch & Lock $49/mo →

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in PlushCare vs. Losing Weight RX (2026 Cost Audit): $19.99/mo Membership + $129 Visit Fees +... is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Abegaz, T. M., Frietze, G., Bhagavathula, A. S., & Ali, A. A. (2026). Cost-Effectiveness of Tirzepatide for the Management of Heart Failure With Preserved Ejection Fraction and Obesity. JACC. Heart failure, 14(8), 103060. https://doi.org/10.1016/j.jchf.2026.103060
  2. Hwang, J. H., Laiteerapong, N., Huang, E. S., & Kim, D. D. (2025). Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. JAMA health forum, 6(3), e245586. https://doi.org/10.1001/jamahealthforum.2024.5586
  3. Legal Information Institute, Cornell Law School. (2024). 21 U.S.C. § 353a — Pharmacy compounding. https://www.law.cornell.edu/uscode/text/21/353a
  4. McEwan, P., Bøg, M., Faurby, M., Foos, V., Lingvay, I., Lübker, C., Miller, R., Toliver, J. C., Yeates, F., & Lincoff, A. M. (2025). Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes. Journal of medical economics, 28(1), 268-278. https://doi.org/10.1080/13696998.2025.2459529
  5. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  6. U.S. Food and Drug Administration. (2024). Human drug compounding: Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding